Core Viewpoint - The company has terminated its licensing and collaboration agreement with Axion Bio, Inc., regaining global rights to its drug candidates IMM2510 and IMM27M, while still receiving a total of $35 million in upfront and milestone payments from Axion [1]. Group 1: Licensing and Collaboration Agreement - The company granted Axion exclusive rights to research, develop, and commercialize several bispecific antibodies targeting PD-L1 and VEGF, including candidate IMM2510, and monoclonal antibodies targeting CTLA-4, including candidate IMM27M [1]. - The termination of the agreement allows the company to reclaim all previously granted licenses, including global development and commercialization rights outside Greater China, while providing Axion with a limited license to wind down its clinical development activities [1]. Group 2: Financial Implications - The termination of the agreement will not affect the $35 million in upfront and milestone payments already received from Axion [1]. Group 3: Future Development Plans - The company expresses confidence in the therapeutic potential of IMM2510 and IMM27M and is committed to accelerating the clinical development of these assets [1].
宜明昂科-B(01541.HK)重获IMM2510及IMM27M的全球权利